<DOC>
	<DOCNO>NCT00984893</DOCNO>
	<brief_summary>The study ass real life effectiveness zoledronic acid management patient osteoporosis 4 year treatment . Zoledronic acid compare oral bisphosphonates ( OBP ) respect change Bone Mineral Density ( BMD ) incidence fracture .</brief_summary>
	<brief_title>Intra-venous Zoledronic Acid Once Yearly</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Patient ambulatory female 45 year age old Postmenopausal woman diagnosis osteoporosis Prescription zoledronic acid OBP per current Canadian monograph Must provide inform consent Any prior use iv bisphosphonates within last 2 year Known secondary osteoporosis aetiology ( hypogonadism premenopausal woman premature menopause , malabsorption , chronic liver disease , inflammatory bowel disease ) Metabolic bone diseases primary secondary hyperparathyroidism , hypoparathyroidism , Paget 's disease bone , Fibrous dysplasia.. Noncorrected hypocalcaemia time zoledronic acid infusion Creatinine clearance &lt; = 30 ml/min Unwillingness inability comply study requirement Concurrent participation clinical trial investigational drug , within last 30 day Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>Bone Mineral density</keyword>
	<keyword>fragility fracture</keyword>
	<keyword>zoledronic acid .</keyword>
	<keyword>Treatment</keyword>
</DOC>